Drugs / MBI 226
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00211497 | Jan → Sep 2003 | acne | BioWest Therapeutics Inc | Completed | No outcome recorded |
| Phase 2 | NCT00211523 | Oct 2000 → Sep 2001 | acne | BioWest Therapeutics Inc | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00027248 | Sep 2000 → Jul 2003 | bacterial infectious disease, fungal infectious disease, infectious disease with sepsis | BioWest Therapeutics Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MBI 226 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00211523 ↗ |
| Route | Topical | “Topical Administration of MBI 226 1.0% Gel” NCT00027248 ↗ |